# PDUFA dates April 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-04

> 44 FDA catalysts are dated in April 2027, including 8 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in April 2027?

PDUFA dates in April 2027: WAKIX® (pitolisant, HRMY) on April 1, 2027; ozekibart (INBX) on April 14, 2027; Epidiolex® (cannabidiol, JAZZ) on April 16, 2027; IDVYNSO (doravirine-islatravir, MRK) on April 22, 2027; deucrictibant (PHVS) on April 23, 2027; Organogenesis Holdings Inc. (ORGO) on April 24, 2027; and 2 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2027-04)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-122377, https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/fda-calendar/2027-04#answer

## PDUFA dates in April 2027

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| April 1, 2027 | Harmony Biosciences Holdings, Inc. | HRMY | WAKIX® (pitolisant) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm) |
| April 14, 2027 | Inhibrx Biosciences, Inc. | INBX | ozekibart |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm) |
| April 16, 2027 | Jazz Pharmaceuticals plc | JAZZ | Epidiolex® (cannabidiol) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm) |
| April 22, 2027 | Merck & Co., Inc. | MRK | IDVYNSO (doravirine-islatravir) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm) |
| April 23, 2027 | Pharvaris N.V. | PHVS | deucrictibant |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm) |
| April 24, 2027 | Organogenesis Holdings Inc. | ORGO |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1661181/000119312526338049/orgo-20260630.htm) |
| April 26, 2027 | UNITED THERAPEUTICS Corp | UTHR | Ofev® (nintedanib) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm) |
| April 28, 2027 | Immunome Inc. | IMNM | varegacestat | desmoid tumors | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm) |

## All catalysts in April 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 1, 2027 | [WAKIX® (pitolisant) NDA/BLA acceptance](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "NDA accepted by FDA in July; target PDUFA date of April 1, 2027 o Designed with enteric coating meant to reduce the potential for GI side effects in patients with narcolepsy, 80 - 90% of whom experience GI symptoms as part of their disease o Enables patients to initiate treatment at a therapeutic dose without titration, an important clinical differentiation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm)) |
| April 1, 2027 | [WAKIX® (pitolisant) PDUFA date](https://sec-api.dev/pdufa/pitolisant) | HRMY |  | scheduled | "Pitolisant GR NDA Under FDA Review, PDUFA Date April 1, 2027; Pitolisant HD Phase 3 Topline Data in 2027, Target PDUFA Date in 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm)) |
| April 2027 | [Isatuximab sc-obds primary completion](https://sec-api.dev/pdufa/isatuximab-sc-obds) | SNY | Plasma Cell Myeloma Refractory | scheduled | "NCT06356571 (A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356571)) |
| April 2027 | [Foralumab nasal primary completion](https://sec-api.dev/pdufa/foralumab-nasal) | TLSA | Multiple System Atrophy | scheduled | "NCT06868628 (A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868628)) |
| April 2027 | [Isatuximab sar650984 primary completion](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT03319667 (A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03319667)) |
| April 2027 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Major Depressive Disorder | scheduled | "NCT05850689 (Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05850689)) |
| April 2027 | [LYNPARZA® (olaparib) primary completion](https://sec-api.dev/pdufa/olaparib) | AZN | Ovarian Cancer; Breast Cancer | scheduled | "NCT04421963 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04421963)) |
| April 2027 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT05331183 (Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05331183)) |
| April 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07231419 (Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07231419)) |
| April 2027 | [SAR444336 primary completion](https://sec-api.dev/pdufa/sar444336) | SNY | Microscopic Colitis | scheduled | "NCT07156175 (A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-08 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156175)) |
| April 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05624749 (Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624749)) |
| April 2027 | [UPLIZNA® (inebilizumab) primary completion](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Neuromyelitis Optica Spectrum Disorder | scheduled | "NCT05549258 (Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549258)) |
| April 14, 2027 | [Ozekibart PDUFA date](https://sec-api.dev/pdufa/ozekibart) | INBX |  | scheduled | "◦In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm)) |
| April 2027 | [Tdv primary completion](https://sec-api.dev/pdufa/tdv) | TAK | Dengue Fever | scheduled | "NCT06579755 (A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-14 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579755)) |
| April 16, 2027 | [Epidiolex® (cannabidiol) PDUFA date](https://sec-api.dev/pdufa/cannabidiol) | JAZZ |  | scheduled | "•The PDUFA target action date for our New Drug Application (NDA) for the oral cannabidiol capsule formulation is April 16, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm)) |
| April 2027 | [Onvansertib primary completion](https://sec-api.dev/pdufa/onvansertib) | CRDF | Metastatic Colorectal Cancer; CRC; KRAS/NRAS Mutation | scheduled | "NCT06106308 (Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-16 (ESTIMATED); Lead Sponsor Cardiff Oncology." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06106308)) |
| April 2027 | [ASTRAZENECA PLC primary completion](https://sec-api.dev/companies/azn/catalysts) | AZN | Heart Failure and Impaired Kidney Function | scheduled | "NCT06307652 (Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307652)) |
| April 2027 | [ABP-692 primary completion](https://sec-api.dev/pdufa/abp-692) | AMGN | Relapsing-remitting Multiple Sclerosis (RRMS) | scheduled | "NCT06700343 (Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06700343)) |
| April 2027 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Breast Cancer, Early Breast Cancer | scheduled | "NCT05774951 (A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05774951)) |
| April 2027 | [AZD5148 primary completion](https://sec-api.dev/pdufa/azd5148) | AZN | Clostridioides Difficile Infection | scheduled | "NCT07285213 (Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-20 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285213)) |
| April 2027 | [BNT162B2 primary completion](https://sec-api.dev/pdufa/bnt162b2) | BNTX | COVID-19 Vaccines | scheduled | "NCT07798648 (A Study of COVID-19 Vaccine(s) in Children and Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-21 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07798648)) |
| April 22, 2027 | [IDVYNSO (doravirine-islatravir) PDUFA date](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK |  | scheduled | "Idvynso is also under review in the U.S. to expand the approved indication in certain virologically suppressed adults with HIV-1 infection to include certain adults who have not previously received antiretroviral treatment; the FDA set a PDUFA date of April 22, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm)) |
| April 2027 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Hepatitis B | scheduled | "NCT06497504 (Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06497504)) |
| April 2027 | [Arumakimig primary completion](https://sec-api.dev/pdufa/arumakimig) | NVS | Still´s Disease | scheduled | "NCT07203001 (A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07203001)) |
| April 23, 2027 | [Deucrictibant PDUFA date](https://sec-api.dev/pdufa/deucrictibant) | PHVS |  | scheduled | "Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)) |
| April 2027 | [Rts,s/as01e vaccine primary completion](https://sec-api.dev/pdufa/rts-s-as01e-vaccine) | GSK | Malaria | scheduled | "NCT07036159 (A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07036159)) |
| April 24, 2027 | [Organogenesis Holdings Inc. PDUFA date](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | scheduled | "During June 2026, the FDA accepted the BLA for review and assigned a PDUFA target action date of April 24, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1661181/000119312526338049/orgo-20260630.htm)) |
| April 2027 | [Part a: atm-avi single dose, cohorts 1-4 primary completion](https://sec-api.dev/pdufa/part-a-atm-avi-single-dose-cohorts-1-4) | PFE | Gram-negative Bacterial Infection | scheduled | "NCT06462235 (A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06462235)) |
| April 2027 | [Ormd-0801 8 mg primary completion](https://sec-api.dev/pdufa/ormd-0801) | ORMP | Type 2 Diabetes Mellitus | scheduled | "NCT06731075 (A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Oramed, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06731075)) |
| April 26, 2027 | [Ofev® (nintedanib) PDUFA date](https://sec-api.dev/pdufa/nintedanib) | UTHR |  | scheduled | "In September 2026, we were notified that the FDA had accepted our sNDA with a user fee goal date of April 26, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| April 2027 | [DII235 primary completion](https://sec-api.dev/pdufa/dii235) | NVS | Lipoprotein Disorder | scheduled | "NCT07235046 (A Study of DII235 in Adults With Elevated Lipoprotein(a)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235046)) |
| April 2027 | [Pg4 multivalent vaccine primary completion](https://sec-api.dev/pdufa/pg4-multivalent-vaccine) | PFE | Pneumococcal Disease | scheduled | "NCT07794748 (A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794748)) |
| April 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity Disease | scheduled | "NCT06987695 (Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987695)) |
| April 2027 | [INCB123667 primary completion](https://sec-api.dev/pdufa/incb123667) | INCY | Ovarian Cancer | scheduled | "NCT07023627 (A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023627)) |
| April 28, 2027 | [Varegacestat PDUFA date](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | scheduled | "Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| April 2027 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06111586 (Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111586)) |
| April 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Hypercholesterolaemia | scheduled | "NCT07610278 (A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610278)) |
| April 2027 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06812988 (Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812988)) |
| April 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia | scheduled | "NCT03836261 (Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03836261)) |
| April 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | scheduled | "NCT04280718 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04280718)) |
| April 2027 | [Darovasertib primary completion](https://sec-api.dev/pdufa/darovasertib) | IDYA | Uveal Melanoma | scheduled | "NCT05907954 ((Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907954)) |
| April 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06517758 (A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517758)) |
| April 2027 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06804811 (A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804811)) |
| April 2027 | [Filricianine primary completion](https://sec-api.dev/pdufa/filricianine) | ISRG | Ureter Injury | scheduled | "NCT07346066 (IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Intuitive Surgical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07346066)) |

Other months: https://sec-api.dev/fda-calendar/2027-03 , https://sec-api.dev/fda-calendar/2027-05. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates April 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-04

```bibtex
@misc{secapidev_fda_calendar_2027_04_20261116,
  title        = {PDUFA dates April 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-04}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_04_20261116","title":"PDUFA dates April 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-04","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
